Published in Clin Exp Immunol on July 01, 1989
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med (2010) 6.34
Tumour cell lines HT-29 and FaDu produce proinflammatory cytokines and activate neutrophils in vitro: possible applications for neutrophil-based antitumour treatment. Mediators Inflamm (2010) 0.88
An important role for granulocytes in the thermal regulation of colon tumor growth. Immunol Invest (2005) 0.84
Phagocyte-generated oxygen metabolites and cellular injury. Lab Invest (1982) 2.43
A test of granulocyte membrane integrity and phagocytic function. Cryobiology (1976) 1.16
Antibody-dependent killing of tumor cells by polymorphonuclear leukocytes. Involvement of oxidative and nonoxidative mechanisms. J Natl Cancer Inst (1984) 1.07
Relationship between antibody-dependent tumour cell lysis and primary granule exocytosis by human neutrophils. Clin Exp Immunol (1987) 0.91
The cytotoxic action of neutrophils on mammalian cells in vitro. Prog Allergy (1988) 0.90
Tumor cells cytotoxicity by granulocytes from peripheral blood of tumor-bearing mice. J Natl Cancer Inst (1978) 0.89
Antibody-dependent tumour cytolysis by human neutrophils: effect of synthetic serine esterase inhibitors and substrates. Immunology (1987) 0.85
A comparison of the cytotoxic potential in polymorphonuclear leukocytes obtained from normal donors and cancer patients. Clin Immunol Immunopathol (1983) 0.84
Serum-associated inhibition of neutrophil Fc receptors in cancer patients. J Natl Cancer Inst (1981) 0.84
Reduced membrane receptor activity of polymorphonuclear leucocytes of cancer patients. Cell Mol Biol Incl Cyto Enzymol (1980) 0.83
Proteasome inhibitors: antitumor effects and beyond. Leukemia (2006) 1.87
Tissue injury in neutrophilic inflammation. Inflamm Res (1997) 1.42
The anti-inflammatory drug nimesulide inhibits neutrophil adherence to and migration across monolayers of cytokine-activated endothelial cells. Respiration (1994) 1.15
The anti-inflammatory drug nimesulide rescues alpha-1-proteinase inhibitor from oxidative inactivation by phagocytosing neutrophils. Respiration (1992) 1.08
Antibody-dependent killing of tumor cells by polymorphonuclear leukocytes. Involvement of oxidative and nonoxidative mechanisms. J Natl Cancer Inst (1984) 1.07
Stromal cell-derived factor-1 as a chemoattractant for follicular center lymphoma B cells. J Natl Cancer Inst (2000) 1.07
Inactivation of neutrophil-derived hypochlorous acid by nimesulide: a potential mechanism for the tissue protection during inflammation. Int J Tissue React (1990) 1.07
Subcutaneous recombinant human erythropoietin for the treatment of anemia in myelodysplastic syndromes. Acta Haematol (1993) 1.05
Mechanisms of tumour cell destruction by PMA-activated human neutrophils. Immunology (1983) 0.97
Inhibition of neutrophil cytolysin production by target cells. Blood (1986) 0.96
HPLC determination of adenosine in human synovial fluid. J Pharm Biomed Anal (2001) 0.91
Relationship between antibody-dependent tumour cell lysis and primary granule exocytosis by human neutrophils. Clin Exp Immunol (1987) 0.91
Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study. Br J Cancer (2006) 0.91
Complex chromosome rearrangements may locate the bcr/abl fusion gene sites other than 22q11. Haematologica (2000) 0.91
Patient-tailored treatments with anti-EGFR monoclonal antibodies in advanced colorectal cancer: KRAS and beyond. Curr Cancer Drug Targets (2012) 0.89
Tumor cell lysis by activated human neutrophils: analysis of neutrophil-delivered oxidative attack and role of leukocyte function-associated antigen 1. Inflammation (1991) 0.88
A novel role of the CX3CR1/CX3CL1 system in the cross-talk between chronic lymphocytic leukemia cells and tumor microenvironment. Leukemia (2011) 0.88
Neutrophil-induced depletion of adenosine triphosphate in target cells: evidence for a hypochlorous acid-mediated process. J Lab Clin Med (1988) 0.87
Augmentation of neutrophil-mediated erythrocyte lysis by cells derived in vitro from human monocytes. Blood (1987) 0.86
Effects of ascorbic acid on neutrophil locomotion. Int Arch Allergy Appl Immunol (1980) 0.85
A multi-scale approach to colorectal cancer: from a biochemical- interaction signaling-network level, to multi-cellular dynamics of malignant transformation. Interplay with mutations and onco-protein inhibitor drugs. Curr Cancer Drug Targets (2012) 0.85
Antibody-dependent tumour cytolysis by human neutrophils: effect of synthetic serine esterase inhibitors and substrates. Immunology (1987) 0.85
Erythrocyte lysis by PMA-triggered neutrophil polymorphonuclears: evidence for an hypochlorous acid-dependent process. Immunology (1985) 0.84
Ox erythrocyte cytotoxicity by phorbol myristate acetate-activated human neutrophils. Scand J Immunol (1983) 0.84
Neutrophil-mediated cellular cytotoxicity triggered by immobilized aggregated IgG: an in vitro model of cell injury during immune complex diseases. J Clin Immunol (1984) 0.84
Serum-associated inhibition of neutrophil Fc receptors in cancer patients. J Natl Cancer Inst (1981) 0.84
Evidence for a reversible functional state of neutrophil chemotactic deactivation. Int Arch Allergy Appl Immunol (1980) 0.84
Induction of neutrophil respiratory burst by tumour necrosis factor-alpha; priming effect of solid-phase fibronectin and intervention of CD11b-CD18 integrins. Clin Exp Immunol (1993) 0.84
Reverse-transcriptase polymerase chain reaction of the maspin gene in the detection of bone marrow breast carcinoma cell contamination. Cancer (2001) 0.84
Down-regulation of K cell activity by neutrophils. Blood (1985) 0.84
Peripheral blood vs. bone marrow for molecular monitoring of BCR-ABL1 levels in chronic myelogenous leukemia, a retrospective analysis in allogeneic bone marrow recipients. Int J Lab Hematol (2009) 0.83
Four-step high-dose sequential chemotherapy with double hematopoietic progenitor-cell rescue for metastatic breast cancer. J Clin Oncol (1995) 0.83
Neutrophil dysfunction and repeated infections: influence of levamisole and ascorbic acid. Br J Dermatol (1980) 0.83
Molecular characterization of an Italian series of sporadic GISTs. Gastric Cancer (2013) 0.83
High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia. Haematologica (1997) 0.83
Role of the oxidative metabolic burst in the antibody-dependent cellular cytotoxicity mediated by neutrophil polymorphonuclears. Exp Hematol (1982) 0.83
DNA damage response pathways and cell cycle checkpoints in colorectal cancer: current concepts and future perspectives for targeted treatment. Curr Cancer Drug Targets (2012) 0.83
Current standards and future strategies in immunochemotherapy of non-Hodgkin's lymphoma. J BUON (2011) 0.82
Role of angiogenesis inhibitors in colorectal cancer: sensitive and insensitive tumors. Curr Cancer Drug Targets (2012) 0.82
Synthetic lethality-based therapeutics: perspectives for applications in colorectal cancer. Curr Cancer Drug Targets (2012) 0.82
Stimulation of neutrophil chemotaxis, adhesiveness, phagocytosis, and hexose monophosphate shunt activity by N-(2-mercaptopropionyl)glycine. Res Exp Med (Berl) (1981) 0.82
Neutrophil functions in acne conglobata. Dermatologica (1979) 0.82
In vitro effects of synthetic chemotactic peptides on neutrophil function. Int Arch Allergy Appl Immunol (1980) 0.82
Neutropenia and impaired neutrophil function in glycogenosis type Ib. J Inherit Metab Dis (1984) 0.81
Neutrophil--mediated cytotoxicity against tumour cells: state of art. Arch Immunol Ther Exp (Warsz) (1992) 0.81
Possible modes of action of nimesulide in controlling neutrophilic inflammation. Arzneimittelforschung (1995) 0.81
Ultrasonography-guided endoscopic stent placement for malignant biliary obstruction: a preliminary report of four cases. Endoscopy (2004) 0.81
The induction of distinct cytokine cascades correlates with different effects of granulocyte-colony stimulating factor and granulocyte/macrophage-colony-stimulating factor on the lymphocyte compartment in the course of high-dose chemotherapy for breast cancer. Cancer Immunol Immunother (1999) 0.80
A monoclonal antibody to platelet glycoproteins IIb and IIIa complex: its use in purifying human megakaryocytes from sternal bone marrow aspirates for immunofluorescence studies of Ia-like antigens. Exp Hematol (1983) 0.80
Long-term survival in patients with metastatic breast cancer receiving intensified chemotherapy and stem cell rescue: data from the Italian registry. Bone Marrow Transplant (2012) 0.80
Dynamic simulations of pathways downstream of ERBB-family, including mutations and treatments: concordance with experimental results. Curr Cancer Drug Targets (2010) 0.80
Sulphasalazine accelerates apoptosis in neutrophils exposed to immune complex: Role of caspase pathway. Clin Exp Pharmacol Physiol (2009) 0.80
Reversal by cimetidine of histamine-induced inhibition of true chemotaxis in neutrophil polymorphonuclears. Res Exp Med (Berl) (1980) 0.80
Anticancer vaccination strategies. Ann Oncol (2004) 0.80
Defective neutrophil chemotaxis corrected by levamisole in Crohn's disease. Acta Hepatogastroenterol (Stuttg) (1978) 0.80
High-dose chemotherapy with tandem autologous transplantation as part of the initial therapy for aggressive non-Hodgkin's lymphoma. Int J Oncol (2000) 0.79
Extracellular cytotoxicity by phagocytosing polymorphonuclear neutrophilic leukocytes: enhancement by a chemotactic stimulus. Exp Hematol (1985) 0.79
Erythrocyte lysis by monocytes: investigations on the mechanism and role of the target cell hydrogen peroxide catabolizing pathways. J Clin Lab Immunol (1987) 0.79
Cefoperazone prevents the inactivation of alpha(1)-antitrypsin by activated neutrophils. Antimicrob Agents Chemother (1999) 0.78
Platelets as inhibitory cells in neutrophil-mediated cytolysis. J Lab Clin Med (1989) 0.78
High-dose mitoxantrone with peripheral blood progenitor cell rescue: toxicity, pharmacokinetics and implications for dosage and schedule. Br J Cancer (1997) 0.78
Modulation of neutrophil Fc and C3b receptors. Relationship with the phagocytic process and activation of the respiratory burst. Inflammation (1983) 0.78
Fluorescence in situ hybridization provides evidence for two-step rearrangement in a masked Ph chromosome formation. Leuk Res (1995) 0.78
[Ultrasound-guided endoscopic drainage, without radiological examination, in patients with neoplastic biliary obstruction. Preliminary results]. Minerva Chir (2004) 0.77
High frequency of trisomy 8 in acute promyelocytic leukemia: a fluorescence in situ hybridization study. Cancer Genet Cytogenet (1997) 0.77
Effect of different cytokines on mammaglobin and maspin gene expression in normal leukocytes: possible relevance to the assays for the detection of micrometastatic breast cancer. Br J Cancer (2005) 0.77
Platelets as scavengers of neutrophil-derived oxidants: a possible defence mechanism at sites of vascular injury. Thromb Haemost (1989) 0.77
Stimulation of granulocyte adhesiveness by the chemotactic peptide N-formyl-L-methionyl-L-phenylalanine. Res Exp Med (Berl) (1980) 0.77
Effects of ascorbic acid on neutrophil function. Studies on normal and chronic granulomatous disease neutrophils. Acta Vitaminol Enzymol (1982) 0.76